957 THE T-CELL EFFECTOR PHENOTYPE PROFILE IN AUTOIMMUNE SCLEROSING CHOLANGITIS DIFFERS FROM THAT OF AUTOIMMUNE HEPATITIS

2012 ◽  
Vol 56 ◽  
pp. S374
Author(s):  
R. Liberal ◽  
C.R. Grant ◽  
B. Holder ◽  
Y. Ma ◽  
G. Mieli-Vergani ◽  
...  
Hepatology ◽  
2017 ◽  
Vol 66 (5) ◽  
pp. 1570-1584 ◽  
Author(s):  
Rodrigo Liberal ◽  
Charlotte R. Grant ◽  
Muhammed Yuksel ◽  
Jonathon Graham ◽  
Alireza Kalbasi ◽  
...  

2017 ◽  
Vol 66 (1) ◽  
pp. S360
Author(s):  
M. Ferreira ◽  
C. Gonçalves ◽  
S. Nobre ◽  
S. Ferreira ◽  
I. Gonçalves

Hepatology ◽  
2015 ◽  
Vol 62 (3) ◽  
pp. 863-875 ◽  
Author(s):  
Rodrigo Liberal ◽  
Charlotte R. Grant ◽  
Beth S. Holder ◽  
John Cardone ◽  
Marc Martinez-Llordella ◽  
...  

Gut ◽  
2012 ◽  
Vol 61 (Suppl 2) ◽  
pp. A119.1-A119
Author(s):  
C R Grant ◽  
R Liberal ◽  
B Holder ◽  
Y Ma ◽  
G Mieli-Vergani ◽  
...  

2002 ◽  
Vol 36 ◽  
pp. 156 ◽  
Author(s):  
James A. Underhill ◽  
Yun Ma ◽  
Dimitrios P. Bogdanos ◽  
Paul Cheeseman ◽  
Giorgina Mieli-Vergani ◽  
...  

Author(s):  
R. Mark Beattie ◽  
Anil Dhawan ◽  
John W.L. Puntis

Autoimmune hepatitis (AIH) 386Autoimmune hepatitis/sclerosing cholangitis overlap syndrome (ASC) 388In paediatrics, two forms of autoimmune liver disease are recognized: • Autoimmune hepatitis (AIH)• AIH/sclerosing cholangitis overlap syndrome (autoimmune sclerosing cholangitis, ASC).• Progressive inflammatory liver disorder, preferentially affecting females, characterized serologically by high levels of transaminases and IgG and presence of autoantibodies, and histologically by interface hepatitis in the absence of a known aetiology....


2015 ◽  
Vol 33 (Suppl. 2) ◽  
pp. 25-35 ◽  
Author(s):  
Guan Wee Wong ◽  
Michael A. Heneghan

For many patients with autoimmune hepatitis (AIH), the presence of extrahepatic features is well recognised both at the time of presentation and during long-term follow-up. Concomitant ‘autoimmune disorders' have been described in 20-50% of patients with AIH, both in adults and children. Indeed, the presence of these associated phenomena has been incorporated into both the original and revised International AIH group scoring systems as an aid to codifying the diagnosis. In acute index presentations, non-specific joint pains sometimes flitting in nature have been reported in 10-60% of patients, and while joint swelling is uncommon, rheumatoid arthritis and mixed connective tissue disease have been reported in 2-4% of patients with AIH. For a majority of patients, these joint symptoms resolve within days of the introduction of immunosuppressive therapy. Rarer features at index presentation include a maculopapular skin rash and unexplained fever, which are features that tend to resolve quickly with treatment. Interestingly, joint pain and stiffness are also well recognised in the context of steroid withdrawal and cessation in AIH. The occasional co-presentation of AIH with coeliac disease is clinically important (1-6%), since for some patients, there is a risk of immunosuppression malabsorption, thus delaying effective treatment. Similarly, the co-existence of selective IgA deficiency (IgAD) can occur in patients with coeliac disease or in isolation. Selective IgAD as a co-existing extraheaptic feature seems to be more common in paediatric patients with AIH. For these patients, they are at an increased risk of respiratory and sinus infections. Although, typically associated with primary sclerosing cholangitis, the presence of inflammatory bowel disease (IBD; both Crohn's disease and ulcerative colitis) has been described in 2-8% of patients with AIH. Interestingly, for patients with autoimmune sclerosing cholangitis, a distinct pattern of IBD has been recently described. Other conditions have been reported at a lower frequency, including Sjogren's syndrome 1-7%, systemic lupus erythematosus 1-3% and glomerulonephritis 1%. Rarer still and at a frequency of <1% include fibrosing alveolitis, haemolytic anaemia, uveitis, mononeuritis multiplex, polymyositis and multiple sclerosis. In contrast, the reported associations between AIH and thyroiditis 8-23%, diabetes 1-10% and psoriasis 3% are commonly seen and notable in clinical practice.


2015 ◽  
Vol 33 (Suppl. 2) ◽  
pp. 181-187 ◽  
Author(s):  
Olivier Chazouillères

Background: Some patients present with features of both primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC) on the one hand and autoimmune hepatitis (AIH) on the other hand, either simultaneously or consecutively. The term ‘overlap syndrome (OS)' is used to describe these settings, but lack of universal agreement on what precisely constitutes an OS has generated considerable confusion. The low prevalence of OS (roughly 10% of PBC or PSC) has made it impracticable to perform randomized controlled trials. It remains unclear whether this syndrome forms a distinct entity or is a variant of PBC, PSC or AIH. Key Messages: Moderate to severe interface hepatitis is a fundamental component and histology is vital in evaluating patients with overlap presentation. Use of the International Autoimmune Hepatitis Group criteria for the diagnosis of OS is not recommended. For PBC-AIH OS, EASL has provided diagnostic criteria and, in most cases, it is possible to define one primary disorder (‘dominant' disease), usually PBC. Patients with OS seem to have a more severe disease compared to conventional PBC. PSC-AIH OS is assumed to exist in a considerable part of mainly young patients with autoimmune liver disease and long-term progression towards cirrhosis seems to occur in the majority of cases. In children, the hepatitic feature can be very dominant, and up to 50% of pediatric AIH have cholangiographic abnormalities suggestive of PSC (autoimmune sclerosing cholangitis). Treatment of OS is empiric and includes ursodeoxycholic acid for the cholestatic component (depending on local policy for PSC) and immunosuppressive agents for the hepatitic component, either simultaneously or sequentially. The dominant clinical feature should be treated first and therapy adjusted according to the response. Conclusions: OS is not uncommon but should not be over-diagnosed in order not to expose unnecessarily PBC or PSC patients to the risk of steroid side effects. Therapy has to be individualized and not be static.


Sign in / Sign up

Export Citation Format

Share Document